FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029168581> ?p ?o ?g. }

• W2029168581 abstract "Second-line systemic therapy for advanced urothelial carcinoma (UC) has substantial unmet needs, and current agents show dismal activity. Second-line trials of metastatic UC have used response rate (RR) and median progression-free survival (PFS) as primary endpoints, which may not reflect durable benefits. A more robust endpoint to identify signals of durable benefits when investigating new agents in second-line trials may expedite drug development. PFS at 6 months (PFS6) is a candidate endpoint, which may correlate with overall survival (OS) at 12 months (OS12) and may be applicable across cytostatic and cytotoxic agents.Ten second-line phase II trials with individual patient outcomes data evaluating chemotherapy or biologics were combined for discovery, followed by external validation in a phase III trial. The relationship between PFS6/RR and OS12 was assessed at the trial level using Pearson correlation and weighted linear regression, and at the individual level using Pearson chi-square test with Yates continuity correction.In the discovery dataset, a significant correlation was observed between PFS6 and OS12 at the trial (R(2) = 0.55, Pearson correlation = 0.66) and individual levels (82%, Қ = 0.45). Response correlated with OS12 at the individual level less robustly (78%, Қ = 0.36), and the trial level association was not statistically significant (R(2) = 0.16, Pearson correlation = 0.37). The correlation of PFS6 (81%, Қ = 0.44) appeared stronger than the correlation of response (76%, Қ = 0.17) with OS12 in the external validation dataset.PFS6 is strongly associated with OS12 and appears more optimal than RR to identify active second-line agents for advanced UC." @default.
• W2029168581 created "2016-06-24" @default.
• W2029168581 creator A5004985848 @default.
• W2029168581 creator A5018275141 @default.
• W2029168581 creator A5022744341 @default.
• W2029168581 creator A5027683140 @default.
• W2029168581 creator A5028129885 @default.
• W2029168581 creator A5030631799 @default.
• W2029168581 creator A5041009445 @default.
• W2029168581 creator A5042318887 @default.
• W2029168581 creator A5044119496 @default.
• W2029168581 creator A5044972820 @default.
• W2029168581 creator A5048477205 @default.
• W2029168581 creator A5049117190 @default.
• W2029168581 creator A5050042851 @default.
• W2029168581 creator A5050435057 @default.
• W2029168581 creator A5052069729 @default.
• W2029168581 creator A5052504518 @default.
• W2029168581 creator A5059219836 @default.
• W2029168581 creator A5068364488 @default.
• W2029168581 creator A5073593424 @default.
• W2029168581 creator A5074756323 @default.
• W2029168581 creator A5080507578 @default.
• W2029168581 creator A5088518431 @default.
• W2029168581 date "2014-04-01" @default.
• W2029168581 modified "2023-09-24" @default.
• W2029168581 title "Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma" @default.
• W2029168581 cites W1521811891 @default.
• W2029168581 cites W1820014750 @default.
• W2029168581 cites W2010949873 @default.
• W2029168581 cites W2040377946 @default.
• W2029168581 cites W2041383926 @default.
• W2029168581 cites W2066984265 @default.
• W2029168581 cites W2070858864 @default.
• W2029168581 cites W2101562875 @default.
• W2029168581 cites W2102116016 @default.
• W2029168581 cites W2114532259 @default.
• W2029168581 cites W2123086444 @default.
• W2029168581 cites W2132379894 @default.
• W2029168581 cites W2137832651 @default.
• W2029168581 cites W2145118120 @default.
• W2029168581 cites W2145526926 @default.
• W2029168581 cites W2152194109 @default.
• W2029168581 cites W2154673624 @default.
• W2029168581 cites W2157244703 @default.
• W2029168581 cites W2162459663 @default.
• W2029168581 doi "https://doi.org/10.1016/j.clgc.2013.09.002" @default.
• W2029168581 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4142680" @default.
• W2029168581 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24220220" @default.
• W2029168581 hasPublicationYear "2014" @default.
• W2029168581 type Work @default.
• W2029168581 sameAs 2029168581 @default.
• W2029168581 citedByCount "25" @default.
• W2029168581 countsByYear W20291685812014 @default.
• W2029168581 countsByYear W20291685812015 @default.
• W2029168581 countsByYear W20291685812016 @default.
• W2029168581 countsByYear W20291685812017 @default.
• W2029168581 countsByYear W20291685812018 @default.
• W2029168581 countsByYear W20291685812020 @default.
• W2029168581 countsByYear W20291685812021 @default.
• W2029168581 crossrefType "journal-article" @default.
• W2029168581 hasAuthorship W2029168581A5004985848 @default.
• W2029168581 hasAuthorship W2029168581A5018275141 @default.
• W2029168581 hasAuthorship W2029168581A5022744341 @default.
• W2029168581 hasAuthorship W2029168581A5027683140 @default.
• W2029168581 hasAuthorship W2029168581A5028129885 @default.
• W2029168581 hasAuthorship W2029168581A5030631799 @default.
• W2029168581 hasAuthorship W2029168581A5041009445 @default.
• W2029168581 hasAuthorship W2029168581A5042318887 @default.
• W2029168581 hasAuthorship W2029168581A5044119496 @default.
• W2029168581 hasAuthorship W2029168581A5044972820 @default.
• W2029168581 hasAuthorship W2029168581A5048477205 @default.
• W2029168581 hasAuthorship W2029168581A5049117190 @default.
• W2029168581 hasAuthorship W2029168581A5050042851 @default.
• W2029168581 hasAuthorship W2029168581A5050435057 @default.
• W2029168581 hasAuthorship W2029168581A5052069729 @default.
• W2029168581 hasAuthorship W2029168581A5052504518 @default.
• W2029168581 hasAuthorship W2029168581A5059219836 @default.
• W2029168581 hasAuthorship W2029168581A5068364488 @default.
• W2029168581 hasAuthorship W2029168581A5073593424 @default.
• W2029168581 hasAuthorship W2029168581A5074756323 @default.
• W2029168581 hasAuthorship W2029168581A5080507578 @default.
• W2029168581 hasAuthorship W2029168581A5088518431 @default.
• W2029168581 hasBestOaLocation W20291685812 @default.
• W2029168581 hasConcept C105795698 @default.
• W2029168581 hasConcept C117220453 @default.
• W2029168581 hasConcept C121608353 @default.
• W2029168581 hasConcept C126322002 @default.
• W2029168581 hasConcept C141341695 @default.
• W2029168581 hasConcept C143998085 @default.
• W2029168581 hasConcept C203092338 @default.
• W2029168581 hasConcept C2524010 @default.
• W2029168581 hasConcept C2780352672 @default.
• W2029168581 hasConcept C2780739268 @default.
• W2029168581 hasConcept C2911057145 @default.
• W2029168581 hasConcept C3019882237 @default.
• W2029168581 hasConcept C3019894029 @default.
• W2029168581 hasConcept C33923547 @default.
• W2029168581 hasConcept C535046627 @default.
• W2029168581 hasConcept C55078378 @default.

• next